Multinodular Goiter

US Endocrinology, 2008;4(2):

Abstract:

Epidemiology and Clinical Manifestations
Thyroid nodules are common in clinical practice and, although the majority are benign, approximately 5% can harbor malignancy. Their prevalence is highly dependent on the method used for detection. With the increased utilization of ultrasound (US) for evaluation of non-thyroid lesions of the neck, the incidental finding of unsuspected thyroid nodules (

Citation US Endocrinology, 2008;4(2):

The evaluation of a patient with a palpable solitary nodule is generally straightforward and usually will include a fine-needle aspiration (FNA) biopsy with or without US guidance. It is important to recognize that in up to 50% of patients with a clinically palpable solitary nodule, ultrasonography will often demonstrate the presence of one or more additional nodules.2 The evaluation and management of patients with multinodular goiters (MNGs) represents a much more difficult problem in the clinical setting. Non-palpable nodules have the same risk for malignancy as palpable nodules of a similar size.3 Although it has been generally postulated that the risk for thyroid cancer is lower in patients with MNG compared with patients with solitary nodules, some studies have shown a similar incidence of cancer in both groups.4,5

The clinical manifestations of patients with MNGs are variable and to a great extent depend on the size and location of the goiter and whether the nodules are hyperfunctioning or not. Many patients with MNGs can be completely asymptomatic, particularly when the goiter is small and the functional status of the thyroid is normal. Other patients may present with a visible goiter that may have been present for years in the absence of other clinical symptoms. However, in some patients thyroid growth may occur in the thoracic cavity (substernal goiters) and result in obstruction or pressure of any of the structures within the cavity. Tracheal compression can result in dyspnea, which is most commonly exertional but can be positional;6,7 dysphagia or hoarseness from compression of recurrent laryngeal nerve are other symptoms that may be seen in patients with large goiters. Hyperthyroidism, either overt or subclinical, may be present in up to 25% of patients with MNG.8
References:
  1. Belfiore A, La Rosa GL, La Porta GA, et al., Cancer risk in patients with cold thyroid nodules: Relevance of iodine intake, sex, age and multinodularity, Am J Med, 1992;93:393–5.
  2. Tan GH, Gharib H, Reading CC, Solitary thyroid nodule: comparison between palpation and ultrasonography, Arch Intern Med, 1995;155:2418–23.
  3. Hagag P, Strauss S,Weiss M, Role of ultrasound-guided fineneedle aspiration biopsy in evaluation of nonpalpable thyroid nodules, Thyroid, 1998;8:989–95.
  4. Papini E, Guglielmi R, Bianchini A, et al., Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features, J Clin Endocrinol Metab, 2002;87:1941–6.
  5. Marqusee E, Benson CB, Frates MC, et al., Usefulness of ultrasonography in the management of nodular thyroid disease, Ann Intern Med, 2000;133:696–700.
  6. Katlic MR, Grillo HC,Wang CA, Substernal goiter. Analysis of 80 patients from Massachusetts General Hospital, Am J Surg, 1985; 149:283–87.
  7. Allo MD, Thompson NW, Rationale for the operative management of substernal goiters, Surgery, 1983;94:969–77.
  8. Rieu M, Bekka S, Sambor B, et al., Prevalence of subclinical hyperthyroidism and relationship between thyroid hormonal status and thyroid ultrasonographic parameters in patients with nontoxic nodular goitre, Clin Endocrinol, 1993;39:67–71.
  9. Cooper DS, Doherty GM, Haugen BR, et al., Management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 2006;16:109–41.
  10. Boelaert K, Horacek J, Holder RL, et al., Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration, J Clin Endocrinol Metab, 2006;91:4295–4301.
  11. Haymart MR, Repplinger DJ, Leverson GE, et al., Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage, J Clin Endocrinol Metab, 2008;93:809–14.
  12. Dolan JG, Thyroid nodules. In: Diagnostic strategies for common medical problems, Panzer RJ, Blac ER, Griner PF (eds), American College of Physicians: Philadelphia, 1991;385–93.
  13. Meier DA, Kaplan MM, Radioiodine uptake and thyroid scintiscanning, Endocrinol Metab Clin North Am, 2001;30:291–313.
  14. Radecki PD, Arger PH, Arenson RL, et al., Thyroid imaging: comparison of high-resolution real-time ultrasound and computed tomography, Radiology, 1984;153:145–7.
  15. AACE/AME Task Force on Thyroid Nodules, American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules, Endocr Pract, 2006;12:63–102.
  16. Carmeci C, Jeffrey RB, McDougall IR, et al., Ultrasound-guided fine-needle aspiration biopsy of thyroid masses, Thyroid, 1998;8:283–9.
  17. Ylagan LR, Farkas T, Dehner LP, Fine needle aspiration of the thyroid: a cytohistologic correlation and study of discrepant cases, Thyroid, 2004;14:35–41.
  18. Werk EEJ, Vernon BM, Gonzalez JJ, et al., Cancer in thyroid nodules: A community hospital survey, Arch Intern Med, 1984; 144:474–6.
  19. Asp AA, Georgitis W,Waldron EJ, et al., Fine needle aspiration of the thyroid: Use in an average health care facility, Am J Med, 1987;83:489–93.
  20. Hamberger JI, Consistency of sequential needle biopsy findings for thyroid nodules: Management implications, Arch Intern Med, 1987;147:97–9.
  21. Baskin HJ, Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules and multinodular goiters, Endocr Pract, 2004;10: 242–5.
  22. Gharib H, Goellner JR, Zinsmeister AR, et al., Fine needle aspiration biopsy of the thyroid. The problem of suspicious cytologic findings, Ann Intern Med, 1984;101:25–8.
  23. Mazzaferri EL, Management of a solitary thyroid nodule, N Engl J Med, 1993;328:553–9.
  24. Maenhaut C, Lefort A, Libert F, et al., Function, proliferation and differentiation of the dog and human thyrocyte, Horm Metab Res Suppl, 1990;3:51–61.
  25. Milazzo G, La Rosa GL, Catalfamo R, et al., Effect of TSH in human thyroid cells: evidence for both mitogenic and antimitogenic effects, J Cell Biochem, 1992;49:231–8.
  26. Castro MR, Caraballo PJ, Morris JC, Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: A meta-analysis, J Clin Endocrinol Metab, 2002;87:4154–9.
  27. Zelmanovitz F, Genro S, Gross JL, Suppressive therapy with Levothyroxine for solitary thyroid nodules: A double blind controlled clinical study and cumulative meta-analyses, J Clin Endocrinol Metab, 1998;83:3881–5.
  28. Berghout A, Wiersinga W, Drexhage H, et al., Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre, Lancet, 1990;336:193–7.
  29. Ross DS, Thyroid hormone suppressive therapy of sporadic nontoxic goiter, Thyroid, 1992;2:263–9.
  30. Ross DS, Thyroid hormone suppressive therapy for thyroid nodules and benign goiter, UpToDate Online, 16 February, 2008.
  31. Franklyn J, Betteridge J, Daykin J, et al., Long-term thyroxine treatment and bone mineral density, Lancet, 1992;340:9–13.
  32. Sawin CT, Geller A,Wolf PA, et al., Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons, N Engl J Med, 1994;331:1249–52.
  33. Franklyn JA, The management of hyperthyroidism, N Engl J Med, 1994;330:1731–8.
  34. Imseis RE, Vanmiddlesworth L, Massie JD, et al., Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism, J Clin Endocrinol Metabol, 1998;83:685–7.
  35. Nygaard B, Faber J, Hegedus L, et al., 131I treatment of nodular non-toxic goitre, Eur J Endocrinol, 1996;134:15–20.
  36. Nygaard B, Hegedus L, Gervil M, et al., Radioiodine treatment of multinodular non-toxic goitre, Br Med J, 1993;307:828–32.
  37. Kay TW, d’Emden MC, Andrews JT, et al., Treatment of non-toxic multinodular goiter with radioactive iodine, Am J Med, 1988;84: 19–22.
  38. Huysmans DA, Hermus AR, Corstens FH, et al., Large, compressive goiters treated with radioiodine, Ann Intern Med, 1994;121:757–62.
  39. Bonnema SJ, Bertelsen H, Mortensen J, et al., The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function, J Clin Endocrinol Metabol, 1999;84: 3636–41.
  40. Wesche MF, Tiel VBMM, Lips P, et al., A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter, J Clin Endocrinol Metabol, 2001;86: 998–1005.
  41. Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al., Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter, J Clin Endocrinol Metabol, 2000;85:3592–6.
  42. Nieuwlaat WA, Huysmans DA, van den Bosch HC, et al., Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter, J Clin Endocrinol Metabol, 2003;88: 3121–9.
  43. Albino CC, Mesa CO Jr, Olandoski M, et al., Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine, J Clin Endocrinol Metabol, 2003;88:2775–80.
  44. Diehl LA, Garcia V, Bonnema SJ, et al., Management of the nontoxic multinodular goiter in Latin America: comparison with North America and Europe, an electronic survey, J Clin Endocrinol Metabol, 2003;88:117–23.
  45. Silva MN, Rubio IG, Romao R, et al., Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitre, Clin Endocrinol, 2004;60:300–308.
  46. Bonnema SJ, Nielsen VE, Hegedus L, Radioiodine therapy in nontoxic multinodular goitre. The possibility of effect-amplification with recombinant human TSH (rhTSH), Acta Oncologica, 2006;45: 1051–8.
  47. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, et al., Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters, J Clin Endocrinol Metabol, 2001;86:5330–36.
  48. Nielsen VE, Bonnema SJ, Hegedus L, Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial, J Clin Endocrinol Metabol, 2006;91: 1317–22.
  49. Nygaard B, Knudsen JH, Hegedus L, et al., Thyrotropin receptor antibodies and Graves’ disease, a side-effect of 131I treatment in patients with nontoxic goiter, J Clin Endocrinol Metabol, 1997;82: 2926–30.
  50. Pieracci FM, Fahey TJ III, Substernal thyroidectomy is associated with increased morbidity and mortality as compared with conventional cervical thyroidectomy, J Am Coll Surg, 2007;205:1–7.
  51. Ross DS, Treatment of toxic adenoma and toxic multinodular goiter, UpToDate Online, 16 February, 2008.
  52. Duntas LH, Cooper DS, Review on the occasion of a decade of recombinant human TSH: Prospects and novel uses, Thyroid, 2008; 18:509–16.
Customize This